Alkermes (ALKS) Research & Development (2010 - 2026)
Alkermes (ALKS) posted quarterly Research & Development of $154.4 million for Q2 2026, up 27.39% year-over-year from $121.2 million in Q2 2025, and down 0.77% quarter-over-quarter from $155.6 million in Q1 2026.
Alkermes (ALKS) Research & Development (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Research & Development for 17 consecutive years, with $154.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 27.39% year-over-year to $154.4 million; the TTM figure through Jun 2026 stood at $545.8 million (up 22.65% YoY), while the FY2025 annual figure was $480.0 million, up 7.57% from the prior year.
- Research & Development declined to $154.4 million in Q2 2026 per ALKS's latest filing, from $155.6 million in the prior quarter.
- Across five years, Research & Development topped out at $293.3 million in Q4 2023 and bottomed at $63.8 million in Q1 2023.
- Historically, Research & Development has averaged $117.7 million across 5 years, with a median of $109.3 million in 2022.
- Annual changes were most pronounced in 2022 — Research & Development soared 697.6% — and 2024, when it tumbled 66.28%.
- Alkermes' Research & Development stood at $103.0 million in 2022, then soared by 184.86% to $293.3 million in 2023, then sank by 66.28% to $98.9 million in 2024, then grew by 21.62% to $120.3 million in 2025, then grew by 28.35% to $154.4 million in 2026.
- Business Quant data shows ALKS's Research & Development at $154.4 million in Q2 2026, $155.6 million in Q1 2026, and $120.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 154.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.36 Mn |
| Mar 31, 2026 | 155.56 Mn |
| Dec 31, 2025 | 120.27 Mn |
| Sep 30, 2025 | 115.63 Mn |
| Jun 30, 2025 | 121.18 Mn |
| Mar 31, 2025 | 122.93 Mn |
| Dec 31, 2024 | 98.89 Mn |
| Sep 30, 2024 | 102.04 Mn |
| Jun 30, 2024 | 119.67 Mn |
| Mar 31, 2024 | 125.62 Mn |
| Dec 31, 2023 | 293.28 Mn |
| Sep 30, 2023 | 64.88 Mn |
| Jun 30, 2023 | 68.23 Mn |
| Mar 31, 2023 | 63.77 Mn |
| Dec 31, 2022 | 102.96 Mn |
| Sep 30, 2022 | 100.43 Mn |
| Jun 30, 2022 | 92.87 Mn |
| Mar 31, 2022 | 95.95 Mn |
| Dec 31, 2021 | -17.23 Mn |
| Sep 30, 2021 | 118.41 Mn |